NLSDays: Ulrica Sehlstedt leads session on financing late stage projects

It is not uncommon for biopharmaceutical companies to build pipelines that offer more development opportunities than the companies themselves are able to pursue. Promising clinical trials can be moved down the priority list and their implementation delayed - which in turn leads to a decrease in asset value.

One possible solution is to package the remaining trials and run them as collaborative projects with investors, CROs and other partners with external funding.

How can this type of biopharma project be financed? And how does a surplus of clinical phase projects affect the life science ecosystem? These issues, among others, are discussed at the 2017 NLSDays under the title A New Mechanism to Fund Excess Clinical Stage Projects – all chaired by Ulrica Sehlstedt, Partner, Arthur D. Little.

Read more about the program here.

About NLSDays

Nordic Life Science Days, which has grown steadily during its first 4 years, has established itself as Northern Europe’s premier life science event for high quality meetings between investors, global companies and Nordic innovative companies. After 4 years in Stockholm, Nordic Life Science Days will now be held in Malmö in the heart of Medicon Valley, September 12-14, 2017. NLSDays is founded by SwedenBIO and produced by Bionordic.